Quoin Pharmaceuticals
QNRX
4 hedge funds and large institutions have $664K invested in Quoin Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
30% less capital invested
Capital invested by funds: $949K → $664K (-$285K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$116K |
| 2 |
HF
HRT Financial
New York
|
+$57.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$116K |
| 2 |
Citigroup
New York
|
-$1K |
| 3 |
PA
Procyon Advisors
Shelton,
Connecticut
|
-$1K |
QNRX Hedge Fund Activity: Q3 2020 in Review
4 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q3 2020, worth a combined $664K — down 30% from $949K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new QNRX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Wedbush Securities, opening a new position worth an estimated $116K. The largest seller was Renaissance Technologies, cutting an estimated $116K.
- 4 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q3 2020, up from 2 in Q2 2020.
- Funds reported $664K of Quoin Pharmaceuticals stock for Q3 2020, down 30% quarter-over-quarter.
- 2 funds opened new Quoin Pharmaceuticals positions in Q3 2020 and 0 closed out, a net change of +2 holders.
- The largest Quoin Pharmaceuticals buyer in Q3 2020 was Wedbush Securities, an estimated $116K added.
- The largest Quoin Pharmaceuticals seller in Q3 2020 was Renaissance Technologies, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2020.